PURPOSE: To determine benefits of cleavage-stage preimplantation genetic screening (PGS) by array comparative genomic hybridization (CGH). METHODS: A retrospective case-control study was performed at a tertiary care university-affiliated medical center. Implantation rate was looked at as a primary outcome. Secondary outcomes included clinical and ongoing pregnancy rates, as well as multiple pregnancy and miscarriage rates. Thirty five patients underwent 39 fresh cycles with PGS by aCGH and 311 similar patients underwent 394 invitro fertilization cycles. RESULT(S): The implantation rate in the CGH group doubled when compared to the control group (52.63 % vs. 19.15 %, p = < 0.001), clinical pregnancy rate was higher (69.23 % vs. 43.91 %, p = 0.0002), ongoing pregnancy rate almost doubled (61.54 % vs. 32.49 %, p = < 0.0001), multiple pregnancy rate decreased (8.33 % vs. 34.38 %, p = 0.0082) and miscarriage rate trended lower (11.11 % vs. 26.01 %, p = 0.13). CONCLUSION: Cleavage stage PGS with CGH is a feasible and safe option for aneuploidy screening that shows excellent outcomes when used in fresh cycles. This is the first report of cleavage stage PGS by CGH showing improved ongoing pregnancy rates.
PURPOSE: To determine benefits of cleavage-stage preimplantation genetic screening (PGS) by array comparative genomic hybridization (CGH). METHODS: A retrospective case-control study was performed at a tertiary care university-affiliated medical center. Implantation rate was looked at as a primary outcome. Secondary outcomes included clinical and ongoing pregnancy rates, as well as multiple pregnancy and miscarriage rates. Thirty five patients underwent 39 fresh cycles with PGS by aCGH and 311 similar patients underwent 394 invitro fertilization cycles. RESULT(S): The implantation rate in the CGH group doubled when compared to the control group (52.63 % vs. 19.15 %, p = < 0.001), clinical pregnancy rate was higher (69.23 % vs. 43.91 %, p = 0.0002), ongoing pregnancy rate almost doubled (61.54 % vs. 32.49 %, p = < 0.0001), multiple pregnancy rate decreased (8.33 % vs. 34.38 %, p = 0.0082) and miscarriage rate trended lower (11.11 % vs. 26.01 %, p = 0.13). CONCLUSION: Cleavage stage PGS with CGH is a feasible and safe option for aneuploidy screening that shows excellent outcomes when used in fresh cycles. This is the first report of cleavage stage PGS by CGH showing improved ongoing pregnancy rates.
Authors: Brooke Hodes-Wertz; Jamie Grifo; Shahin Ghadir; Brian Kaplan; Carl A Laskin; Michael Glassner; Santiago Munné Journal: Fertil Steril Date: 2012-06-07 Impact factor: 7.329
Authors: Nathan R Treff; Brynn Levy; Jing Su; Lesley E Northrop; Xin Tao; Richard T Scott Journal: Mol Hum Reprod Date: 2010-05-19 Impact factor: 4.025
Authors: Ashley W Tiegs; Brooke Hodes-Wertz; David H McCulloh; Santiago Munné; James A Grifo Journal: J Assist Reprod Genet Date: 2016-03-17 Impact factor: 3.357
Authors: Lorena Rodrigo; Emilia Mateu; Amparo Mercader; Ana Cristina Cobo; Vanessa Peinado; Miguel Milán; Nasser Al-Asmar; Inmaculada Campos-Galindo; Sandra García-Herrero; Pere Mir; Carlos Simón; Carmen Rubio Journal: Biomed Res Int Date: 2014-04-29 Impact factor: 3.411
Authors: Daniel Luna; Roly Hilario; Julio Dueñas-Chacón; Rocío Romero; Patricia Zavala; Lucy Villegas; Javier García-Ferreyra Journal: Clin Med Insights Reprod Health Date: 2015-11-12